← FDA DRUG APPROVALS

FDA ANDA · ANDA206409

ELETRIPTAN HYDROBROMIDE

Sponsor: ZYDUS PHARMS

APPLICATION
ANDA206409
TYPE
ANDA
ORIGINAL APPROVAL
2017-06-16
LATEST ACTION
2020-11-24
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

ELETRIPTAN HYDROBROMIDEPrescription
ELETRIPTAN HYDROBROMIDE EQ 20MG BASE · TABLET · ORAL
ELETRIPTAN HYDROBROMIDEPrescription
ELETRIPTAN HYDROBROMIDE EQ 40MG BASE · TABLET · ORAL

Approval history

2020-11-24Labeling · Supplement 3 · standardAP
2017-06-16UNKNOWN · Original · standard — Letter ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →